CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 45 enrolled
Drug / intervention
Patients not treatedother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03937284
NCT03937284N/ACompleted

Lipoprotein Lipidic Composition, Lipopolysaccharide Binding Protein, and Bacterial Endotoxin Exposure in Parkinson's Disease: A Pilot Study

University of Milan·observational·Posted May 3, 2019·Updated May 3, 2019

In Brief

An observational study evaluating Patients not treated for Parkinson Disease. Completed, enrolled 45 participants across 1 site.

Detailed Summary

Patients with Parkinson's disease (PD) present an impaired intestinal permeability with consequent lipopolysaccharide (LPS) translocation in the systemic circulation. Plasmatic lipoproteins play a key role in the detoxification of LPS. The investigators aim to study the relationships between lipoprotein chemical composition and plasma LPS circulation in PD.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesItaly

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 3, 2019
Enrollment StartMay 3, 2016
Primary CompletionOct 20, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.2 years ago

Interventions

Patients not treatedother